Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.649 USD | +3.02% | -2.20% | -55.55% |
Business Summary
Number of employees: 11
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
ViraxClear and ViraxImmune
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom, Hong Kong, Singapore, China, British Virgin Islands
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 37 | 31/12/12 |
Jason Davis
DFI | Director of Finance/CFO | 52 | 01/05/22 |
Mark Ternouth
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
Tomasz George
CTO | Chief Tech/Sci/R&D Officer | 40 | 31/01/21 |
Nigel McCracken
COO | Chief Operating Officer | - | 31/08/23 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Nelson Haight
BRD | Director/Board Member | 58 | - |
Evan Norton
BRD | Director/Board Member | 49 | - |
James Foster
CEO | Chief Executive Officer | 37 | 31/12/12 |
Mark Ternouth
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
Yair Erez
BRD | Director/Board Member | 50 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,361,903 | 1,729,013 ( 73.20 %) | 0 | 73.20 % |
Company contact information
Sector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-55.55% | 1.53M | |
+0.67% | 42.4B | |
+46.17% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- VRAX Stock
- Company Virax Biolabs Group Limited